Guided by our organotypic data, we next assessed the effects of CAF-derived NID2 on tumor growth in vivo in the context of standard-of-care gemcitabine/Abraxane (nab-paclitaxel) chemotherapy (2). This evidence concerns the gene NID2 and neoplasm.